
NTLA Valuation
Intellia Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
NTLA Relative Valuation
NTLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NTLA is overvalued; if below, it's undervalued.
Historical Valuation
Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 28.51 is considered Fairly compared with the five-year average of -11.57. The fair price of Intellia Therapeutics Inc (NTLA) is between 6.19 to 61.35 according to relative valuation methord.
Relative Value
Fair Zone
6.19-61.35
Current Price:12.78
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.69
P/B
Median3y
2.60
Median5y
4.98
-25.84
FCF Yield
Median3y
-18.34
Median5y
-12.16
Competitors Valuation Multiple
The average P/S ratio for NTLA's competitors is 12.49, providing a benchmark for relative valuation. Intellia Therapeutics Inc Corp (NTLA) exhibits a P/S ratio of 30.10, which is 140.90% above the industry average. Given its robust revenue growth of -42.54%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch

BRDG
Bridge Investment Group Holdings Inc
10.690
USD
-0.19%

MATW
Matthews International Corp
24.710
USD
-0.24%

BLMN
Bloomin' Brands Inc
10.000
USD
0.00%

OCS
Oculis Holding AG
17.650
USD
0.00%

MSC
Studio City International Holdings Ltd
4.750
USD
+3.98%

GIC
Global Industrial Co
27.580
USD
+0.84%

TMP
Tompkins Financial Corp
62.850
USD
-0.70%

ZYME
Zymeworks Inc
13.485
USD
-3.75%

OPFI
OppFi Inc
11.190
USD
-0.53%

RDFN
Redfin Corp
11.300
USD
-0.36%
FAQ

Is Intellia Therapeutics Inc (NTLA) currently overvalued or undervalued?
Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 28.51 is considered Fairly compared with the five-year average of -11.57. The fair price of Intellia Therapeutics Inc (NTLA) is between 6.19 to 61.35 according to relative valuation methord.

What is Intellia Therapeutics Inc (NTLA) fair value?

How does NTLA's valuation metrics compare to the industry average?

What is the current P/B ratio for Intellia Therapeutics Inc (NTLA) as of Jul 25 2025?

What is the current FCF Yield for Intellia Therapeutics Inc (NTLA) as of Jul 25 2025?

What is the current Forward P/E ratio for Intellia Therapeutics Inc (NTLA) as of Jul 25 2025?
